Chronic psychological stress is increasingly recognized as a biological modifier of cancer progression through sustained neuroendocrine and immune dysregulation. This narrative review summarizes current evidence on how chronic activation of the hypothalamic-pituitary-adrenal axis and sympathetic nervous system reshapes the tumor immune microenvironment and may influence response to anticancer therapy. Glucocorticoid and adrenergic signaling can alter immune -cell trafficking, differentiation, metabolism, and effector function, promoting expansion or functional reprogramming of tumor -associated macrophages, myeloid -derived suppressor cells, and neutrophils while impairing cytotoxic T -cell and natural killer - cell activity. Experimental studies provide particularly strong evidence for glucocorticoid-dependent neutrophil reprogramming and neutrophil extracellular trap ormation as mechanisms linking chronic stress with prometastatic microenvironmental changes. Persistent beta -adrenergic signaling may additionally promote metabolic dysfunction and exhaustion of tumor-infiltrating T cells. Emerging clinical studies in mel anoma and non- small-cell lung cancer have associated pretreatment emotional distress with inferior outcomes during immune checkpoint blockade; however, these observations remain non- causal. Current evidence supports chronic stress as a potentially modifiab le component of tumor -immune interactions, but prospective mechanistic and interventional studies are required before stress - related parameters or adrenergic modulation can be used as validated predictive or therapeutic tools in oncology.
No takes yet. Share an insight, caveat, or question.
Hryvkova et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: